Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

NAD+ vs MOTS-c

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors NAD+

NAD+ has the stronger human evidence, but mostly for oral precursors: randomized trials show nicotinamide riboside raises blood NAD+ and nicotinamide mononucleotide improved muscle insulin sensitivity in prediabetic women, while MOTS-c has no human treatment trial at all. The caveat is that injectable and intravenous NAD+, the form clinics sell, has only an 11 person pharmacokinetic pilot. NAD+ is also not prohibited in sport, while MOTS-c is banned at all times.

Verified: Verified Oct 28, 2026
MOTS-cSponsoredFrom Bodybuilding Peptides

Which is better, NAD+ or MOTS-c?

NAD+ wins on evidence grade (human RCT for precursors versus animal only), on WADA status, and on access, since oral precursors are lawful supplements that need no prescription. Both injectable forms are in regulatory limbo: NAD+ is a nominated 503A bulk substance compounded under FDA's interim policy, and MOTS-c is not on the bulks list but is covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding, which is not binding and may be revisited. Anyone choosing NAD+ should know the trial evidence supports oral NR and NMN, not infusions, and that a 2025 meta-analysis found no effect on muscle mass or function. [1] [2] [3] [4] [6] [9] [10] [11] [12]

How do NAD+ and MOTS-c compare?

NAD+ and MOTS-c compared by dimension
DimensionNAD+FavoredMOTS-c
Evidence grade [1] [2] [6] [7] [8]Human RCT, for oral precursors: NR 1,000 mg per day raised blood NAD+ about 60% in 24 older adults; NMN 250 mg per day improved muscle insulin sensitivity about 25% in 25 prediabetic women.Animal only. Mouse studies of obesity, insulin resistance, and running capacity; human data are exercise induced blood levels and a genetic association.
What it is [5] [6]A coenzyme (a dinucleotide, not a peptide) used in energy metabolism and consumed by sirtuins, PARP, and CD38.A 16 amino acid peptide encoded in the mitochondrial 12S rRNA gene.
Mechanism [3] [5] [6]Restores cellular NAD+ that falls with age; precursors enter the salvage pathway. Intravenous NAD+ is largely broken down in blood before reaching cells.Activates AMPK via folate cycle inhibition and AICAR accumulation, raising muscle glucose uptake and fat oxidation in mice.
Injectable form evidence [3] [6] [7]One open label pilot: a 6 hour infusion in 11 healthy men, plasma NAD+ did not rise until the second hour and no clinical endpoints were measured.No human study of injected MOTS-c; mice received 0.5 to 15 mg/kg.
Side effects [1] [2] [6]Oral precursors well tolerated in trials; IV NAD+ commonly causes chest pressure, nausea, cramping, and flushing when infused quickly.No human safety data; theoretical added glucose lowering with diabetes drugs.
FDA and compounding status [9] [10] [12] [13]Not FDA approved. Nominated for the 503A bulks list and compounded under FDA's interim enforcement policy where states permit; oral NR and NMN are sold as supplements.Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous or intramuscular injection only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).
WADA status [11]Not prohibited as a substance.Prohibited at all times under S4.4 (metabolic modulators), where it is named as an activator of AMP-activated protein kinase.
Note: Under WADA method M2, intravenous infusions or injections above 100 mL per 12 hour period are prohibited for athletes outside legitimate hospital care, which can apply to NAD+ drips.
Cost and access [9] [10] [12]Oral NR or NMN roughly 30 to 100 USD per month over the counter; IV sessions 300 to 1,000 USD; compounded injections roughly 150 to 400 USD per month.Only as a single-ingredient compounded product on a patient-specific prescription under HHS's October 28, 2026 draft enforcement discretion policy, if its conditions are met; it is not on the 503A bulks list. No verified compounded price yet.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

NAD+ and MOTS-c: grade, status, and cost
AttributeNAD+MOTS-c
ClassCoenzyme (a dinucleotide, not a peptide) central to redox metabolism and sirtuin and PARP signaling; sold as intravenous or subcutaneous NAD+ and as oral precursorsMitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNA
What it isA coenzyme, not a peptide, whose precursors raise blood NAD+ in human RCTs; clinical benefits and IV NAD+ itself remain largely unproven.A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics.
EvidenceEvidence: Human RCT evidenceEvidence: Animal-only evidence
FDA statusRegulatory: In FDA review (Category 1)Regulatory: HHS interim policy (draft)
CompoundingNAD+ (nicotinamide adenine dinucleotide) is not an FDA approved drug. As of the last verification date it is in FDA's 503A Category 1, the list of nominated bulk substances still under evaluation that FDA has not flagged as a significant safety risk. Under FDA's interim policy, FDA does not intend to act against a state-licensed 503A pharmacy that compounds with a Category 1 substance if the bulk ingredient comes from FDA-registered manufacturers with a valid certificate of analysis and the other 503A conditions are met. That protection lasts until FDA decides on listing by final rule or removes NAD+ from Category 1. One salt form, the beta disodium salt trihydrate, is in Category 3 and is not covered. State boards may add their own limits.MOTS-c is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADAWADA: Not WADA prohibitedWADA: WADA prohibited
RoutesOral precursors: nicotinamide riboside, nicotinamide mononucleotide (dietary supplements), Intravenous infusion of NAD+ (clinics, compounded), Subcutaneous or intramuscular NAD+ injection (compounded), Intranasal and transdermal products exist without absorption dataSubcutaneous injection (as sold), Intraperitoneal injection (animal studies)
Typical costIV NAD+ at a published clinic menu costs about 450 to 900 USD per session for 500 to 1,000 mg (member prices from 400 USD); compounded subcutaneous NAD+ through telehealth is about 79 to 199 USD per month. Oral NR or NMN supplements are sold over the counter. Prices checked 2026-09-22 on published provider and pharmacy price pages.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Last verified

Has NAD+ been tested directly against MOTS-c?

No published trial has compared NAD+ and MOTS-c directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do NAD+ and MOTS-c cost?

Typical cost of NAD+ and MOTS-c
DimensionNAD+MOTS-c
Typical cost$79 to $199 per monthNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Price detailNAD+ price by channelMOTS-c price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the NAD+ page and the MOTS-c page.

Frequently asked questions

Is NAD+ or MOTS-c better for energy and aging?

Neither has shown an effect on energy, aging, or longevity in human trials. NAD+ precursors raise blood NAD+ and NMN improved muscle insulin sensitivity in one trial, but a 2025 meta-analysis found no effect on muscle mass or function. MOTS-c evidence is limited to mice. [1] [2] [4] [7]

Does IV NAD+ work better than oral precursors?

There is no evidence that it does. The only published infusion study was an 11 person pharmacokinetic pilot with no clinical endpoints, and it found that much of the infused NAD+ is broken down and excreted. The randomized trial evidence is for oral nicotinamide riboside and nicotinamide mononucleotide. [1] [2] [3]

Can athletes use either one?

MOTS-c is prohibited at all times under WADA section S4.4 (metabolic modulators). NAD+ itself is not a prohibited substance, but IV drips above 100 mL per 12 hours fall under the prohibited method M2 outside legitimate hospital care. [11]

Do I need a prescription?

Not for oral NAD+ precursors, which are dietary supplements. Injectable NAD+ requires a prescription filled by a 503A compounding pharmacy. MOTS-c is not on the 503A bulks list; HHS's October 28, 2026 draft enforcement discretion policy says HHS does not intend to take enforcement action against compounding it as a single-ingredient product on a patient-specific prescription, if the policy's conditions are met. The draft is not binding. Neither is an FDA approved drug. [9] [10] [12]

Can they be combined?

No study has tested NAD+ and MOTS-c together, so there is no evidence on the combination's benefit or safety. Both are proposed to affect glucose metabolism, so people on diabetes medications should involve their prescriber. [2] [6]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018PubMed 29599478, 2018
  2. [2]Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021PubMed 33888596, 2021
  3. [3]Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019PubMed 31572171, 2019
  4. [4]Prokopidis K et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025PubMed 40275690, 2025
  5. [5]Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab 2018PubMed 29514064, 2018
  6. [6]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015PubMed 25738459, 2015
  7. [7]Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021PubMed 33473109, 2021
  8. [8]Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY) 2021PubMed 33468709, 2021
  9. [9]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
  10. [10]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). NAD+ vs MOTS-c: evidence, cost, and legality. https://peptideagent.ai/compare/nad-plus-vs-mots-c
HTML link
<a href="https://peptideagent.ai/compare/nad-plus-vs-mots-c">NAD+ vs MOTS-c: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.